When to Order Imaging for Ovarian Cancer Screening: ACR Appropriateness Decoded
You are evaluating a patient concerned about her ovarian cancer risk and asking about screening options. She is asymptomatic, but wants to be proactive. Do you order a pelvic ultrasound? A CT scan? For most patients, the answer is no imaging at all. Deciding when screening is indicated—and when it is not—is critical to avoid the harms of over-investigation, including false positives, unnecessary anxiety, and invasive procedures. Here is a clear, scannable guide to the American College of Radiology (ACR) Appropriateness Criteria for ovarian cancer screening to help you make evidence-based decisions.
What Does ACR Ovarian Cancer Screening Cover?
This ACR Appropriateness Criteria document provides guidance for imaging in asymptomatic adult women for the purpose of ovarian cancer screening. The recommendations are stratified based on two key factors: menopausal status (premenopausal vs. postmenopausal) and individual risk level (average risk vs. high risk). High-risk status is typically defined by the presence of pathogenic genetic mutations (e.g., BRCA1, BRCA2) or a strong family history consistent with hereditary cancer syndromes.
Crucially, these guidelines do not apply to patients who are symptomatic (e.g., presenting with pelvic pain, bloating, or a palpable mass) or who have a known adnexal mass found incidentally or on physical exam. Those clinical scenarios represent a diagnostic workup, not screening, and are covered under separate ACR guidelines, such as those for Adnexal Mass. This document is exclusively for the evaluation of asymptomatic individuals to determine the utility of screening imaging.
What Imaging Should I Order for Ovarian Cancer Screening? Recommendations by Clinical Scenario
The ACR guidance on ovarian cancer screening is clear and conservative, reflecting the current evidence on the balance of benefits and harms. The recommendations hinge almost entirely on the patient’s underlying risk status.
For an Adult, postmenopausal, average-risk patient or an Adult, premenopausal, average-risk patient, the ACR recommendations are identical and definitive. All imaging modalities, including all forms of ultrasound (transvaginal, transabdominal, color Doppler), MRI, CT, and PET/CT, are rated Usually Not Appropriate. This is based on multiple large-scale clinical trials that have failed to show a mortality benefit for screening the general population. The potential harms from false-positive findings, which can lead to unnecessary surgeries and complications, are considered to outweigh any potential benefit in this group.
The guidance changes for high-risk individuals. For an Adult, premenopausal, high-risk patient or an Adult, postmenopausal, high-risk patient, the recommendations are again identical across menopausal status. In these scenarios, pelvic ultrasound modalities—including US color Doppler ovaries, US pelvis transabdominal, and US pelvis transvaginal—are rated as May Be Appropriate. This rating reflects that while evidence is still evolving, screening with transvaginal ultrasound (often in combination with serum CA-125 testing) is a strategy frequently employed for surveillance in this specific high-risk cohort. More advanced cross-sectional imaging, such as MRI and CT, remains Usually Not Appropriate for the initial screening setting due to radiation dose (for CT) and lack of proven superiority over ultrasound.
ACR Imaging Recommendations Table
| Clinical Scenario | Top Procedure | ACR Rating | Adult RRL | Pediatric RRL |
|---|---|---|---|---|
| Adult. Ovarian cancer screening. Postmenopausal. Average risk. | US pelvis transvaginal | Usually not appropriate | O 0 mSv | O 0 mSv [ped] |
| Adult. Ovarian cancer screening. Premenopausal. Average risk. | US pelvis transvaginal | Usually not appropriate | O 0 mSv | O 0 mSv [ped] |
| Adult. Ovarian cancer screening. Premenopausal. High risk. | US pelvis transvaginal | May be appropriate | O 0 mSv | O 0 mSv [ped] |
| Adult. Ovarian cancer screening. Postmenopausal. High risk. | US pelvis transvaginal | May be appropriate | O 0 mSv | O 0 mSv [ped] |
Adult vs. Pediatric Ovarian Cancer Screening Imaging: Radiation Dose Tradeoffs
The ACR guidelines for ovarian cancer screening are focused on adult populations, as the condition is exceedingly rare in children. However, the provided relative radiation level (RRL) data includes pediatric estimates to inform general principles of radiation safety. For any imaging involving ionizing radiation, such as Computed Tomography (CT) or Positron Emission Tomography (PET)/CT, adherence to the As Low As Reasonably Achievable (ALARA) principle is paramount, especially in younger patients.
Children are inherently more radiosensitive than adults, and their longer life expectancy provides a greater window for potential long-term effects of radiation exposure to manifest. For this reason, pediatric CT protocols are always optimized to use the lowest possible dose. As shown in the data, a CT of the abdomen and pelvis that might fall into a 1-10 mSv range for an adult could be in a 3-10 mSv range for a child, with a higher RRL symbol reflecting the heightened biological risk concern. Fortunately, for ovarian cancer screening, non-ionizing radiation modalities like ultrasound are the only ones considered potentially appropriate, eliminating radiation risk entirely.
Imaging Protocol Details for Ovarian Cancer Screening
Once you’ve decided on the right study, the protocol matters. A well-executed protocol is key to diagnostic accuracy. Our protocol guides cover detailed technique, contrast parameters, and interpretation principles for various imaging studies. While pelvic ultrasound is the primary modality in this guideline, understanding protocols for other studies is essential for comprehensive practice. Our guides cover studies such as:
Tools to Help You Order the Right Study
Navigating imaging guidelines can be complex. GigHz provides a suite of tools designed to support clinical decision-making and streamline the ordering process for physicians and trainees.
For scenarios beyond ovarian cancer screening, the Imaging Appropriateness Selector tool provides direct access to the full library of ACR guidelines, covering thousands of clinical variants across all organ systems. It helps ensure you’re always referencing the most current, evidence-based recommendations.
To ensure studies are performed correctly, the Imaging Protocol Library offers detailed, step-by-step protocols for hundreds of common and advanced imaging procedures. This resource is invaluable for standardizing care and ensuring diagnostic quality across your institution.
When discussing the risks and benefits of imaging with patients, especially concerning studies with ionizing radiation, the Radiation Dose Calculator is an essential tool. It helps you estimate and track cumulative radiation exposure, facilitating informed conversations and adherence to ALARA principles.
Why is routine imaging not recommended for average-risk women for ovarian cancer screening?
Large-scale, randomized controlled trials have shown that screening average-risk women with ultrasound and/or CA-125 does not reduce mortality from ovarian cancer. However, it does lead to a significant number of false-positive results, which often result in unnecessary anxiety, further testing, and invasive surgical procedures (including oophorectomy) that carry their own risks and complications. The consensus is that for the general population, the harms of screening currently outweigh the benefits.
What defines a “high-risk” patient who might be a candidate for ovarian cancer screening?
A “high-risk” patient is typically someone with a significantly increased lifetime risk of developing ovarian cancer. This is most commonly due to a known pathogenic or likely pathogenic mutation in a cancer susceptibility gene, such as BRCA1 (up to 44% lifetime risk) or BRCA2 (up to 17% lifetime risk). It can also include individuals with a strong family history suggestive of a hereditary cancer syndrome (e.g., Lynch syndrome) even without confirmed genetic testing. Risk assessment should be performed by a clinician familiar with genetic cancer syndromes.
What is the role of the CA-125 blood test in ovarian cancer screening?
The CA-125 blood test is a tumor marker that can be elevated in ovarian cancer, but it has low specificity and can be elevated by many benign conditions (e.g., endometriosis, fibroids, menstruation). It is not recommended as a standalone screening tool for the general population. In high-risk individuals, it is often used in conjunction with transvaginal ultrasound as part of a multimodal screening strategy, typically starting between ages 30-35, but this should be guided by a specialist in gynecologic oncology or genetics.
If an adnexal mass is found incidentally on a CT for another reason, do these screening guidelines apply?
No. These guidelines are strictly for asymptomatic screening. The discovery of an adnexal mass, whether incidentally or in a symptomatic patient, shifts the clinical context from screening to diagnosis and characterization. This situation is addressed by a different set of ACR Appropriateness Criteria, specifically for “Adnexal Mass,” which provides guidance on the best imaging modalities (often MRI or dedicated ultrasound) to characterize the lesion and determine the likelihood of malignancy.
Why are CT and MRI “Usually Not Appropriate” for screening, even in high-risk patients?
For screening, the ideal test is one that is sensitive, safe, accessible, and cost-effective. Transvaginal ultrasound (TVUS) fits these criteria better than CT or MRI for this specific purpose. CT involves ionizing radiation, which is undesirable for a routine screening test, and it is less sensitive than TVUS for subtle ovarian changes. MRI, while providing excellent soft tissue detail without radiation, is more expensive, less widely available, and has not been shown to be superior to TVUS as a primary screening tool in a way that justifies its routine use. MRI’s role is typically in problem-solving and characterizing masses found on ultrasound.
Frequently Asked Questions
Why is routine imaging not recommended for average-risk women for ovarian cancer screening?
Large-scale, randomized controlled trials have shown that screening average-risk women with ultrasound and/or CA-125 does not reduce mortality from ovarian cancer. However, it does lead to a significant number of false-positive results, which often result in unnecessary anxiety, further testing, and invasive surgical procedures (including oophorectomy) that carry their own risks and complications. The consensus is that for the general population, the harms of screening currently outweigh the benefits.
What defines a “high-risk” patient who might be a candidate for ovarian cancer screening?
A “high-risk” patient is typically someone with a significantly increased lifetime risk of developing ovarian cancer. This is most commonly due to a known pathogenic or likely pathogenic mutation in a cancer susceptibility gene, such as BRCA1 (up to 44% lifetime risk) or BRCA2 (up to 17% lifetime risk). It can also include individuals with a strong family history suggestive of a hereditary cancer syndrome (e.g., Lynch syndrome) even without confirmed genetic testing. Risk assessment should be performed by a clinician familiar with genetic cancer syndromes.
What is the role of the CA-125 blood test in ovarian cancer screening?
The CA-125 blood test is a tumor marker that can be elevated in ovarian cancer, but it has low specificity and can be elevated by many benign conditions (e.g., endometriosis, fibroids, menstruation). It is not recommended as a standalone screening tool for the general population. In high-risk individuals, it is often used in conjunction with transvaginal ultrasound as part of a multimodal screening strategy, typically starting between ages 30-35, but this should be guided by a specialist in gynecologic oncology or genetics.
If an adnexal mass is found incidentally on a CT for another reason, do these screening guidelines apply?
No. These guidelines are strictly for asymptomatic screening. The discovery of an adnexal mass, whether incidentally or in a symptomatic patient, shifts the clinical context from screening to diagnosis and characterization. This situation is addressed by a different set of ACR Appropriateness Criteria, specifically for “Adnexal Mass,” which provides guidance on the best imaging modalities (often MRI or dedicated ultrasound) to characterize the lesion and determine the likelihood of malignancy.
Why are CT and MRI “Usually Not Appropriate” for screening, even in high-risk patients?
For screening, the ideal test is one that is sensitive, safe, accessible, and cost-effective. Transvaginal ultrasound (TVUS) fits these criteria better than CT or MRI for this specific purpose. CT involves ionizing radiation, which is undesirable for a routine screening test, and it is less sensitive than TVUS for subtle ovarian changes. MRI, while providing excellent soft tissue detail without radiation, is more expensive, less widely available, and has not been shown to be superior to TVUS as a primary screening tool in a way that justifies its routine use. MRI’s role is typically in problem-solving and characterizing masses found on ultrasound.
Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026
